Supplementary Figure 2 from Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Dalantercept, an Activin Receptor–like Kinase-1 Ligand Trap, in Patients with Advanced Cancer

Johanna C. Bendell,Michael S. Gordon,Herbert I. Hurwitz,Suzanne F. Jones,David S. Mendelson,Gerard C. Blobe,Neeraj Agarwal,Carolyn H. Condon,Dawn Wilson,Amelia E. Pearsall,Yijun Yang,Ty McClure,Kenneth M. Attie,Matthew L. Sherman, Sunil Sharma

crossref（2023）

引用 0|浏览25

暂无评分

摘要

PDF file - 43K, Tumor blood flow response to dalantercept as assessed by DCE-MRI. Best response measured as maximum percent change from baseline in median Ktrans at day 15.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要